Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Scientists Invited to Access New Cutting-edge Technology Platform

Published: Thursday, May 01, 2014
Last Updated: Thursday, May 01, 2014
Bookmark and Share
UCB announces that it has launched its ‘Technology Platform Access’, a collaboration programme for the discovery and development of novel antibodies against potential therapeutic targets.

Today medicine discovery is a sophisticated process that integrates scientific innovation with cutting-edge technology and through UCB’s ‘Technology Platform Access’, academic and research groups can apply to gain access to our new automated antibody discovery platform which is capable of rapidly generating, selecting, producing and evaluating new human antibody-based medicines for patients.

Commenting on the new programme, Dr Ismail Kola, Executive Vice President, UCB NewMedicines™, said “Partnerships between academic groups and industry are vital to the future of scientific discovery. We are hugely committed to seeking new ways of working and creating super-networks to advance medical research and improve health”. He added, “This programme offers the chance for groups to access our state-of-the-art technology as well as collaborate with our premier discovery team”.

In December 2013, UCB announced the successful completion of a $5.5 million investment in a new laboratory with cutting-edge robotic equipment for the fully automated discovery of antibodies. This has permitted us to greatly increase our antibody discovery capacity and coincides with the successful conclusion of a project to develop new technology to mine the natural repertoire of antibody sequence.

In conjunction with strong antibody engineering and expression capabilities, plus structural biology expertise, this represents a novel and efficient route to the generation of high quality antibodies, not only against human targets but also for the generation of research tools for proof-of-concept models.

UCB are now accepting proposals from academic and research groups for collaborative projects on antibody targets, using this antibody discovery platform at our immunology research centre of excellence facility in the UK.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB Announces US and EU Regulatory Filings for Brivaracetam
Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures.
Tuesday, January 27, 2015
UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
Strategic collaboration commences with three discovery programs in areas of high patient need.
Friday, April 04, 2014
UCB CEO to Chair IMI Board for a Second Term
Roch Doliveux to spearhead industry’s commitment to world’s biggest public-private partnership in biopharmaceutical research and innovation.
Wednesday, April 02, 2014
UCB and Sanofi Partner for Innovation in Immune-Mediated Diseases
Goal is to identify novel small molecule therapies to address a wide range of immune-mediated diseases.
Friday, March 14, 2014
UCB and Biogen Idec Enter Agreement
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s innovative therapies to patients in new markets.
Friday, January 31, 2014
Online Challenge to Find Next Generation of Breakthrough Medicines
UCB announces the global launch of its ‘Innovation Challenge’ which seeks to find rare phenotypes.
Tuesday, January 28, 2014
Multimillion Pound Investment in UK Life Sciences Research and Development
UCB invests over £3 million in new bespoke cutting-edge robotic platform for UK R&D HQ.
Wednesday, December 11, 2013
UCB Receives CHMP Positive Opinion for Cimzia in Active PsA
Positive opinion is supported by data from the RAPID™-PsA study.
Monday, October 28, 2013
Vectura and UCB to Collaborate and Share Expertise in Severe Inflammatory
Collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory.
Tuesday, October 01, 2013
UCB Announces Third Research Collaboration with Harvard University
New Research Alliance project to focus on human microbiome to develop new therapeutic applications in immunology.
Wednesday, October 10, 2012
UCB Announces Start of C-EARLY™ Study for Cimzia® in RA
Phase III study to evaluate Cimzia® (certolizumab pegol) in adult patients with early, active, moderate to severe rheumatoid arthritis who have not been exposed to disease-modifying antirheumatic drugs.
Thursday, August 23, 2012
New Real World Clinical Data Showed Vimpat® (lacosamide) Effective in Achieving Seizure Control
At final follow-up 31.1% patients reported =50% seizures reduction and 9.8% were seizure free.
Friday, July 06, 2012
UCB to Showcase Immunology Portfolio at EULAR 2012
Data to be presented on certolizumab pegol, epratuzumab and CDP7851/AMG 785.
Thursday, July 05, 2012
UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target
New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK.
Thursday, March 15, 2012
UCB CEO to Chair Innovative Medicines Initiative Board
Roch Doliveux confirms industry’s commitment to unique EU public-private partnership.
Monday, March 12, 2012
Scientific News
Breaking Through the Barriers to Lab Innovation
Here we examine the drivers behind the move for greater innovation, the challenges and current trends in laboratory informatics, and the tools that can be used to break these barriers.
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Fruit Fly Pheromone Flags Great Real Estate for Starting a Family
Finding could aid efforts to control mosquito-borne diseases like malaria by manipulating odorants
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Analyzing Protein Structures in Their Native Environment
Enhanced-sensitivity NMR could reveal new clues to how proteins fold.
Supercoiled DNA is Far More Dynamic Than the “Watson-Crick” Double Helix
Researchers have imaged in unprecedented detail the three-dimensional structure of supercoiled DNA, revealing that its shape is much more dynamic than the well-known double helix.
Mini-kidneys Successfully Grown from Stem Cells
Researchers from Murdoch Childrens Research Institute have perfected a method of turning stem cells into mini-kidneys for use in drug screening, disease modelling and cell therapy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos